Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takeda Applies for Successor of Candesartan
November 1, 2010
- Takara Bio Begins Leukemia Gene Therapy in 1st Subject
November 1, 2010
- Iressa Fails to Extend OS in 1st Line Treatment for NSCLC
November 1, 2010
- Teijin's Gout Drug Launched in Canada
November 1, 2010
- FDA Rejects Eisai's Application for Lorcaserin
November 1, 2010
- Kowa to Present Peretinoin Data at AASLD 2010
November 1, 2010
- Number of Hub Medical Institutions for Clinical Trials Reduced to 20
November 1, 2010
- Astellas to Transfer Intal to sanofi-aventis
November 1, 2010
- Dabigatran Approved for SPAF in the US
November 1, 2010
- Cabazitaxel Improves Survival in Prostate Cancer Patients
November 1, 2010
- Astellas Licenses Dysuria Drug from ASKA
November 1, 2010
- MSD Launches Higher-Strength Asmanex
November 1, 2010
- BI's Combination Drug for Hypertension Receives EU Approval
November 1, 2010
- Afinitor plus Sandostatin Extended PFS in NET Patients: Novartis
November 1, 2010
- Shionogi Allies with Swedish Academia
November 1, 2010
- CDFS Subcommittee to Discuss Safety Measures for Mylotarg
November 1, 2010
- Precaution Statements to Be Revised for Ketoprofen-Based OTC Drugs
November 1, 2010
- Takeda Sets Up Global Business Development Organization
November 1, 2010
- PMDA to Have Fewer Active Officials Dispatched from Korosho
November 1, 2010
- Daiichi Sankyo Healthcare Voluntarily Recalls Skin Cream
November 1, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…